Navigation Links
Cell Biosciences Introduces Kits for Oncoprotein Analysis
Date:1/21/2009

PALO ALTO, Calif., Jan. 21 /PRNewswire/ -- Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the launch of its first kits for the analysis of specific oncoproteins on the Firefly(TM) 3000 Protein Analysis System. The new kits are optimized for characterization of proteins in the MEK and ERK families, which play critical roles in cancer cell survival and proliferation. Drug developers have targeted signaling via MEK and ERK with a number of kinase inhibitor anticancer drugs.

The Firefly 3000 system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which generally precludes protein analysis in precious clinical samples. By using the new analysis kits on the Firefly 3000 system, researchers can obtain detailed profiles of MEK and ERK signaling in as few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK phosphorylation can be studied in cancer cells and solid tumor samples.

"We developed these oncoprotein analysis kits in response to strong interest from our cancer research customers," said Wilhelm Lachnit, Ph.D., Vice President of Research and Development. "They enable robust analysis of MEK and ERK phosphoprotein signaling, and provide a unique window into the specific actions of kinase inhibitor drugs in limited samples."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nano-fluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.

http://www.cellbiosciences.com

info@cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
2. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
3. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
4. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
5. Cell Biosciences Delivers Next Generation System to Stanford University
6. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
7. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
8. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
11. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
(Date:2/28/2017)... 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical ... of autoimmune diseases, asthma and allergic diseases and ... quarter and full year ended December 31, 2016 ... business and clinical highlights. "During 2016, ... pipeline by starting five clinical trials across our ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... well as to their processing and transport properties. With the Litesizerâ„¢ 100 ... of samples. The Litesizerâ„¢ 100 gives rapid and accurate insight into particle systems, ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel and ... 15 years of meeting this unique need within the biotechnology and pharmaceutical industries ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):